title: Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
abstract: Decree No. 2012-1116 of 2 October 2012 on medico-economic assignments of the French National Authority for Health (Haute autorité de santé, HAS) significantly alters the conditions for accessing the health products market in France. This paper presents a theoretical framework for interpreting the results of the economic evaluation of health technologies and summarises the facts available in France for developing benchmarks that will be used to interpret incremental cost-effectiveness ratios. This literature review shows that it is difficult to determine a threshold value but it is also difficult to interpret then incremental cost effectiveness ratio (ICER) results without a threshold value. In this context, round table participants favour a pragmatic approach based on "benchmarks" as opposed to a threshold value, based on an interpretative and normative perspective, i.e. benchmarks that can change over time based on feedback.
authors.affiliation: Délégation à la recherche clinique et à l'innovation, CHRU, Lille, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Dervaux
authors.affiliation: Laboratoire Lilly, Neuilly sur Seine, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Baseilhac
authors.affiliation: Comité économique des produits de santé, Paris, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Fagon
authors.affiliation: Direction de la sécurité sociale, Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Biot
authors.affiliation: AMGEN, Neuilly sur Seine, France.
authors.forename: Corinne
authors.initials: C
authors.lastname: Blachier
authors.affiliation: Laboratoire Janssen Cilag, Issy les Moulineaux, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Braun
authors.affiliation: Medtronic, Boulogne Billancourt, France.
authors.forename: Frédérique
authors.initials: F
authors.lastname: Debroucker
authors.affiliation: CEMKA-EVAL, Bourg la Reine, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Detournay
authors.affiliation: Comité économique des produits de santé, Paris, France.
authors.forename: Carine
authors.initials: C
authors.lastname: Ferretti
authors.affiliation: Boston Scientific, Saint Quentin en Yvelines, France.
authors.forename: Muriel
authors.initials: M
authors.lastname: Granger
authors.affiliation: LEEM, Paris, France.
authors.forename: Chrystel
authors.initials: C
authors.lastname: Jouan-Flahault
authors.affiliation: ANAP, Paris, France.
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Lussier
authors.affiliation: Direction générale de la santé, Paris, France.
authors.forename: Arlette
authors.initials: A
authors.lastname: Meyer
authors.affiliation: GlaxoSmithKline, Marly le Roy, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Muller
authors.affiliation: CNAMTS, Paris, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Pigeon
authors.affiliation: MSD-Chibret, Courbevoie, France.
authors.forename: Rima
authors.initials: R
authors.lastname: De Sahb
authors.affiliation: Association française des hémophiles, Paris, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Sannié
authors.affiliation: Laboratoire Roche, Boulogne Billancourt, France.
authors.forename: Claudine
authors.initials: C
authors.lastname: Sapède
authors.affiliation: Institut Pasteur, Paris, France.
authors.forename: Muriel
authors.initials: M
authors.lastname: Vray
mesh_terms: D019985:Benchmarking / Q000592:standards*; D020811:Biomedical Technology / Q000191:economics; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D004864:Equipment and Supplies / Q000191:economics*; D005602:France; D006077:Government Agencies / Q000331:legislation & jurisprudence*; D062069:Inventions / Q000191:economics; D009313:National Health Programs / Q000191:economics*; D004364:Pharmaceutical Preparations / Q000191:economics*; D019057:Quality-Adjusted Life Years
chemical_list: D004364:Pharmaceutical Preparations